Neumora Financial Statements From 2010 to 2024

NMRA Stock   10.39  0.02  0.19%   
Neumora Therapeutics, financial statements provide useful quarterly and yearly information to potential Neumora Therapeutics, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Neumora Therapeutics, financial statements helps investors assess Neumora Therapeutics,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Neumora Therapeutics,'s valuation are summarized below:
Market Capitalization
1.7 B
Earnings Share
(1.20)
We have found one hundred six available fundamental ratios for Neumora Therapeutics,, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Neumora Therapeutics, last-minute market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Neumora Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neumora Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 634.6 K, Selling General Administrative of 30.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neumora financial statements analysis is a perfect complement when working with Neumora Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Neumora Therapeutics, Correlation against competitors.

Neumora Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities17.9 M25.1 M6.6 M
Slightly volatile
Common Stock Shares Outstanding168.7 M158.8 M153.5 M
Slightly volatile
Total Liabilities25.8 M27.1 M131.5 M
Slightly volatile
Short and Long Term Debt Total4.9 M5.2 M2.9 M
Slightly volatile
Other Current Liabilities15.9 M18 M9.1 M
Slightly volatile
Current Deferred Revenue15.8 M21.3 M8.6 M
Slightly volatile
Non Currrent Assets Other1.2 M1.2 M1.2 M
Slightly volatile
Other Assets5.1 M4.7 M1.7 M
Slightly volatile
Cash And Short Term Investments392.4 M454 M249.3 M
Slightly volatile
Net Receivables606.6 K939 K286.2 K
Slightly volatile
Liabilities And Stockholders Equity426.2 M496.2 M263.7 M
Slightly volatile
Other Current Assets12.8 M23.4 M5.1 M
Slightly volatile
Short Term Debt7.1 M6.8 M1.8 M
Slightly volatile
Common Stock16.2 K18.4 K13.8 K
Slightly volatile
Property Plant Equipment6.8 M12.2 M5.1 M
Slightly volatile
Other Liabilities557.7 K722.2 K436 K
Slightly volatile
Inventory70 K45 K111 K
Slightly volatile
Deferred Long Term Liabilities2.6 M3.3 M2.1 M
Slightly volatile
Non Current Liabilities Other147.2 K155 K370.8 K
Pretty Stable

Neumora Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization634.6 K668 K447 K
Slightly volatile
Selling General Administrative30.1 M45.5 M14.9 M
Slightly volatile
Other Operating Expenses180.6 M188.2 M119.5 M
Slightly volatile
Research Development150.5 M142.7 M104.6 M
Slightly volatile
Total Operating Expenses180.5 M187.5 M119.5 M
Slightly volatile
Reconciled Depreciation523.9 K668 K231.9 K
Slightly volatile
Cost Of Revenue1.3 M668 K1.6 M
Very volatile
Selling And Marketing Expenses534.4 K601.2 K654.6 K
Slightly volatile

Neumora Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings44.7 M50.3 M54.8 M
Slightly volatile
Depreciation442.2 K668 K226.5 K
Slightly volatile
Capital Expenditures111.2 K117 K1.1 M
Slightly volatile
Total Cash From Financing Activities176.2 M231.9 M223.2 M
Slightly volatile
Change To Netincome19.1 M20.1 M70.3 M
Slightly volatile
Stock Based Compensation8.7 M17.2 M3.8 M
Slightly volatile
Other Non Cash Items61.6 M63.6 M71.8 M
Very volatile
Issuance Of Capital Stock162.4 M233.4 M181.1 M
Pretty Stable
End Period Cash Flow335.2 M375.3 M231.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.170.17519.261
Slightly volatile
Inventory Turnover26.5448.5518.5284
Slightly volatile
Days Of Inventory On Hand7.397.7824.9957
Slightly volatile
Payables Turnover2.081.98221.053
Slightly volatile
Cash Per Share1.862.85831.5838
Slightly volatile
Days Payables Outstanding175184397
Very volatile
Income Quality0.430.69210.3522
Slightly volatile
Net Debt To EBITDA2.041.96671.9561
Slightly volatile
Current Ratio20.3419.046620.0782
Slightly volatile
Graham Number5.839.93494.3484
Slightly volatile
Debt To Equity0.00580.00650.0071
Slightly volatile
Capex Per Share7.0E-47.0E-40.007
Slightly volatile
Interest Debt Per Share0.0170.01910.0208
Slightly volatile
Debt To Assets0.00540.00610.0067
Slightly volatile
Days Of Payables Outstanding175184397
Very volatile
Ebt Per Ebit0.851.25221.0332
Pretty Stable
Total Debt To Capitalization0.00570.00640.007
Slightly volatile
Debt Equity Ratio0.00580.00650.0071
Slightly volatile
Quick Ratio20.3419.046620.0777
Slightly volatile
Net Income Per E B T0.80.90.981
Slightly volatile
Cash Ratio17.3614.895419.0251
Slightly volatile
Days Of Inventory Outstanding7.397.7824.9957
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00071.0447
Very volatile
Debt Ratio0.00540.00610.0067
Slightly volatile

Neumora Fundamental Market Drivers

Cash And Short Term Investments454 M

Neumora Upcoming Events

7th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Neumora Therapeutics, Financial Statements

Neumora Therapeutics, stakeholders use historical fundamental indicators, such as Neumora Therapeutics,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Neumora Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neumora Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Neumora Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neumora Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue21.3 M15.8 M
Cost Of Revenue668 K1.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:
Check out the analysis of Neumora Therapeutics, Correlation against competitors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.20)
Return On Assets
(0.38)
Return On Equity
(0.77)
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.